169 related articles for article (PubMed ID: 30481041)
1. DMAKO-20 as a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme.
Cui J; Zhang X; Huang G; Zhang Q; Dong J; Sun G; Meng Q; Li S
Mol Pharm; 2019 Jan; 16(1):409-421. PubMed ID: 30481041
[TBL] [Abstract][Full Text] [Related]
2. Selective Antitumor Effect of Shikonin Derived DMAKO-20 on Melanoma through CYP1B1.
Cui J; Zhou X; Huang J; Cui J; Chen J
Curr Cancer Drug Targets; 2020 Nov; ():. PubMed ID: 33200710
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of DMAKO-05, a novel shikonin derivative, and its metabolism in rat liver microsome.
Zhang X; Wang RB; Zhou W; Xiao S; Meng QQ; Li SS
AAPS PharmSciTech; 2015 Apr; 16(2):259-66. PubMed ID: 25273027
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.
Huang G; Zhao HR; Meng QQ; Zhang QJ; Dong JY; Zhu BQ; Li SS
Eur J Med Chem; 2018 Jan; 143():166-181. PubMed ID: 29174813
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
Wang R; Zhang X; Song H; Zhou S; Li S
Bioorg Med Chem Lett; 2014 Sep; 24(17):4304-7. PubMed ID: 25127868
[TBL] [Abstract][Full Text] [Related]
6. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.
Song H; Li H; Shen X; Liu K; Feng H; Cui J; Wei W; Sun X; Fan Q; Bao W; Zhou H; Qian L; Nie H; Cheng X; Du Z
Acta Biomater; 2024 Mar; 177():456-471. PubMed ID: 38331131
[TBL] [Abstract][Full Text] [Related]
7. Shikonin Derivative DMAKO-05 Inhibits Akt Signal Activation and Melanoma Proliferation.
Yang YY; He HQ; Cui JH; Nie YJ; Wu YX; Wang R; Wang G; Zheng JN; Ye RD; Wu Q; Li SS; Qian F
Chem Biol Drug Des; 2016 Jun; 87(6):895-904. PubMed ID: 26804061
[TBL] [Abstract][Full Text] [Related]
8. The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells.
Ruparelia KC; Lodhi S; Ankrett DN; Wilsher NE; Arroo RRJ; Potter GA; Beresford KJM
Bioorg Med Chem Lett; 2019 Jun; 29(11):1403-1406. PubMed ID: 30935796
[TBL] [Abstract][Full Text] [Related]
9. Novel hypoxia-targeting Pt(iv) prodrugs.
Xu Z; Zhao J; Gou S; Xu G
Chem Commun (Camb); 2017 Mar; 53(26):3749-3752. PubMed ID: 28303266
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of shikonin and alkannin derivatives as potential anticancer agents via a prodrug approach.
Wang RB; Zhou W; Meng QQ; Zhang X; Ding J; Xu Y; Song HL; Yang K; Cui JH; Li SS
ChemMedChem; 2014 Dec; 9(12):2798-808. PubMed ID: 25234005
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of Synthesized 1,4-Naphthoquinone Oxime Derivatives on Selected Human Cancer Cell Lines.
Zhang Q; Dong J; Cui J; Huang G; Meng Q; Li S
Chem Pharm Bull (Tokyo); 2018; 66(6):612-619. PubMed ID: 29863062
[TBL] [Abstract][Full Text] [Related]
13. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
[TBL] [Abstract][Full Text] [Related]
14. Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
Jiang Y; Li X; Hou J; Huang Y; Jia Y; Zou M; Zhang J; Wang X; Xu W; Zhang Y
Eur J Med Chem; 2016 Oct; 121():649-657. PubMed ID: 27322756
[TBL] [Abstract][Full Text] [Related]
15. CYP1B1: A Promising Target in Cancer Drug Discovery.
Fabris M; Luiza Silva M; de Santiago-Silva KM; de Lima Ferreira Bispo M; Goes Camargo P
Anticancer Agents Med Chem; 2023; 23(9):981-988. PubMed ID: 36655529
[TBL] [Abstract][Full Text] [Related]
16. Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.
Wang Z; Chen Y; Drbohlav LM; Wu JQ; Wang MZ
J Biomol Screen; 2016 Dec; 21(10):1090-1099. PubMed ID: 28139960
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of novel alkannin derivatives with potent selectivity on comprehensive analysis.
Dai ZQ; Gao F; Zhang ZJ; Lu MJ; Luo YJ; Zhang T; Shang BX; Gu YH; Zeng Q; Gao S; Guo ZQ; Xu B; Lei HM
Phytomedicine; 2023 Aug; 117():154912. PubMed ID: 37295023
[TBL] [Abstract][Full Text] [Related]
18. Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents.
Huang G; Dong JY; Zhang QJ; Meng QQ; Zhao HR; Zhu BQ; Li SS
Eur J Med Chem; 2019 Mar; 165():160-171. PubMed ID: 30677614
[TBL] [Abstract][Full Text] [Related]
19. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
20. Target ROS to induce apoptosis and cell cycle arrest by 5,7-dimethoxy-1,4-naphthoquinone derivative.
Li K; Wang B; Zheng L; Yang K; Li Y; Hu M; He D
Bioorg Med Chem Lett; 2018 Feb; 28(3):273-277. PubMed ID: 29305189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
